Sudeep Pharma Ltd IPO

Pros

• • Sudeep Pharma claims to be a leading manufacturer of mineral-based pharmaceuticals, food, nutrition, and speciality ingredients in India, including iron phosphate and encapsulated preservatives such as sorbic acid and calcium propionate. The company reports having a portfolio of over 100 products, developed through its long-term focus on excipients and speciality ingredient solutions. Its presence in a regulated, high-barrier segment, supported by established manufacturing and compliance capabilities, positions it among the limited number of players operating at scale in this industry.
• • Sudeep Pharma claims to serve over 1,100 customers across the pharmaceutical, food, nutrition, and fast-moving consumer goods (FMCG) sectors, including more than 40 multinational companies as of June 30, 2025. The company reports that 14 Fortune 500 companies are part of its customer base, with long-term associations reflected in an average 7.08-year relationship with its five largest customers.
• • Sudeep Pharma operates four manufacturing facilities in Vadodara with 12 production lines and a combined annual capacity of 72,246 metric tonnes (MT) as of June 30, 2025. These facilities, equipped with automation systems and proprietary processes such as encapsulation, spray drying, granulation, and liposomal preparation, support the production of both mineral-based ingredients and speciality nutrition components. The company also reports holding 35 global accreditations and 10 product-specific approvals, including US Food and Drug Administration (USFDA) clearance for mineral-based food ingredients at one facility, along with access to 15 overseas warehouses that support storage and distribution.